FDA
-
-
-
-
-
-
-
FDA approves therapy for pediatric patients with serious rare blood disease (AZN) (ALXN)
-
-
-
-
-
-
-
Alexion Reports Fourth Quarter and Full Year 2020 Results
-
-
-
-
-
-
-
Alexion Announces Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition
-
-
-
-
-
-
-
Alexion (ALXN) and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis
-
-
-
-
-
-
-
Alexion Pharma (ALXN) Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS in PNH Met Primary Endpoint
-
-
-
-
-
-
-
Alexion (ALXN) to Acquire Portola (PTLA) for $18 Per Share
-
-
-
-
-
-
-
Alexion Completes Acquisition of Achillion
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

